A phase I dose escalation study to assess the maximum tolerated dose and feasibility of combining oral capecitabine (Xeloda) and conformal radiotherapy (CRT) for patients with unresectable hepatocellular carcinoma, multiple hepatic metastases or cholangiocarcinoma.

Trial Profile

A phase I dose escalation study to assess the maximum tolerated dose and feasibility of combining oral capecitabine (Xeloda) and conformal radiotherapy (CRT) for patients with unresectable hepatocellular carcinoma, multiple hepatic metastases or cholangiocarcinoma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Cholangiocarcinoma; Liver cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Nov 2007 Status changed from recruiting to discontinued (lack of accrual).
    • 18 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top